麻豆传媒

Note that some links may require registration or subscription.

A Houston physician was for his role in a $5 million pill-mill scheme, according to the Department of Justice.

In a world first, the U.K. as a potential cure for sickle cell disease and beta thalassemia; the FDA is still reviewing the product for the two blood disorders. (AP)

U.S. public health officials of the monoclonal antibody nirsevimab (Beyfortus) for infant respiratory syncytial virus (RSV) immunization. (CNN)

Pediatric cancer mortality in the U.S. , a CDC report showed, but declines stalled for Black and Hispanic kids.

Maternal and infant mortality in the U.S. "remains at crisis-level," a found.

Meanwhile, the CDC and World Health Organization found last year, driven by declining vaccination rates.

Columbia University set up for the victims of ob/gyn Robert Hadden, MD, who was sentenced to 20 years in prison. (New York Times)

The CDC detailed America's attributed to work at a cannabis production facility. (Morbidity and Mortality Weekly Report)

Johns Hopkins physician Darren Klugman, MD, was placed on leave after . (CBS News)

Over for colon cancer screening couldn't be processed, mainly due to patient-related reasons. (Cancer Epidemiology, Biomarkers and Prevention)

Diagnostic tests were more often completed when rather than a telehealth appointment. (JAMA Network Open)

HHS announced a to advise on research and innovation.

In an effort to combat pulse oximeter inaccuracies for people of color, the FDA with suggestions for improving the quality of premarket studies and will again convene an in February 2024 to discuss the matter.

Meanwhile, the agency approved as first-line treatment for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma, drugmaker Merck said.

And Pfizer for men with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis based on results of the phase III EMBARK trial.

And in other agency news, Janet Woodcock, MD, said she ; the long-time senior FDA leader currently serves as principal deputy commissioner. (Reuters)

The Federal Trade Commission warned two diet influencers on social media over s without properly disclosing they were paid by industry.

Comment